Aristolochic acid-associated cancers: a public health risk in need of global action
S Das, S Thakur, M Korenjak, VS Sidorenko… - Nature Reviews …, 2022 - nature.com
Aristolochic acids (AAs) are a group of naturally occurring compounds present in many plant
species of the Aristolochiaceae family. Exposure to AA is a significant risk factor for severe …
species of the Aristolochiaceae family. Exposure to AA is a significant risk factor for severe …
Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma
Z Liu, Y Zhao, P Kong, Y Liu, J Huang, E Xu, W Wei… - Cancer Cell, 2023 - cell.com
Integrated molecular analysis of human cancer has yielded molecular classification for
precise management of cancer patients. Here, we analyzed the whole genomic …
precise management of cancer patients. Here, we analyzed the whole genomic …
A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study
K Li, Y Lin, Y Luo, X **ong, L Wang, K Durante, J Li… - Molecular cancer, 2022 - Springer
Background The tRNA-derived small RNAs (tsRNAs) are produced in a nuclease-
dependent manner in responses to variety of stresses that are common in cancers. We focus …
dependent manner in responses to variety of stresses that are common in cancers. We focus …
Noncoding RNA mutations in cancer
H Zhou, X Hao, P Zhang, S He - Wiley Interdisciplinary Reviews …, 2023 - Wiley Online Library
Cancer is driven by both germline and somatic genetic changes. Efforts have been devoted
to characterizing essential genetic variations in cancer initiation and development. Most …
to characterizing essential genetic variations in cancer initiation and development. Most …
[HTML][HTML] Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD …
X Yan, H Duan, Y Ni, Y Zhou, X Wang, H Qi… - International Journal of …, 2022 - Elsevier
Background Clinical benefit of neoadjuvant immunotherapy in resectable esophageal
squamous cell carcinoma (ESCC). remains unclear. This study evaluated the efficacy and …
squamous cell carcinoma (ESCC). remains unclear. This study evaluated the efficacy and …
SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis
L Feng, K Zhao, L Sun, X Yin, J Zhang, C Liu… - Journal of Translational …, 2021 - Springer
Background Solute carrier family 7 member 11 (SLC7A11) is a component of
cysteine/glutamate transporter, which plays a key role in tumor growth; however, its …
cysteine/glutamate transporter, which plays a key role in tumor growth; however, its …
RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma
Y Cui, C Zhang, S Ma, Z Li, W Wang, Y Li, Y Ma… - Journal of Experimental …, 2021 - Springer
Background Long non-coding RNA (LncRNA) controls cell proliferation and plays a
significant role in the initiation and progression of esophageal squamous cell carcinoma …
significant role in the initiation and progression of esophageal squamous cell carcinoma …
Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting
W Liu, L **e, YH He, ZY Wu, LX Liu, XF Bai… - Nature …, 2021 - nature.com
Esophageal cancer (EC) is a type of aggressive cancer without clinically relevant molecular
subtypes, hindering the development of effective strategies for treatment. To define …
subtypes, hindering the development of effective strategies for treatment. To define …
Genomic alterations driving precancerous to cancerous lesions in esophageal cancer development
Esophageal squamous cell carcinoma (ESCC) develops through a series of increasingly
abnormal precancerous lesions. Previous studies have revealed the striking differences …
abnormal precancerous lesions. Previous studies have revealed the striking differences …
Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a …
G Zhang, J Yuan, C Pan, Q Xu, X Cui, J Zhang, M Liu… - …, 2023 - thelancet.com
Background Immune checkpoint inhibitors combined with chemotherapy as a neoadjuvant
therapy have been applied to the treatment of esophageal squamous cell carcinoma …
therapy have been applied to the treatment of esophageal squamous cell carcinoma …